Provectus Biopharmaceuticals Inc. Announces Abstract Available On PV-10 For Chemoablation Of Liver Cancers At ESMO 17th World Congress On Gastrointestinal Cancer

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT,, a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), announced that the abstract titled, “Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver” to be presented at the ESMO 17th World Congress on Gastrointestinal Cancer is now available online at:

Help employers find you! Check out all the jobs and post your resume.

Back to news